Moreover, MASLD and MASH are highly associated (50%–80%) with impaired insulin response, type 2 diabetes, dyslipidaemia, hypertriglyceridemia, hypertension, and more than 90% of obese patients with type 2 diabetes have MASH (Le et al., 2023). This evidence concerns the gene INS and hypertriglyceridemia.